The new CDO title comes alongside Asper’s existing responsibilities, Amsterdam-based Wright Medical said.
The new digital division will focus on the company’s digital surgery strategy to develop new platforms, accelerate surgical solutions and drive software tech innovation across the business, Wright Medical said. The division will build upon the company’s existing Blueprint software, Wright added.
Asper joined Wright in 2017 as strategy, tech and corp dev senior VP. Prior to joining Wright, Asper served as a principal for Deloitte Consulting, the company said.
Wright Medical said that it also tapped former IMASCAP CEO Jean Chaoui as its new chief software technology officer. Chaoui will report to Asper in the newly created digital division.
“Since the acquisition of IMASCAP, we, along with our physician partners, have developed a multi-year strategy and pipeline that I believe will be transformational for shoulder surgery. The opportunities for Wright in further developing and deploying our digital technology, including our Blueprint platform into other areas, are enormous. We have a leadership position in our software enabling technology, and we want to take full advantage of that lead to maximize the revenue potential of our pipeline across all of our businesses. Building out our digital ecosystem is a key component of our business strategy, from a surgeon and patient perspective, as well as in terms of future business growth and product development. Jason’s proven track record of success will serve us well as we focus on fully developing the Blueprint technology for shoulder as rapidly as possible, expanding our digital technology in lower extremities and evaluating additional opportunities for our digital technology in other areas of medtech,” prez & CEO Robert Palmisano said in a press release.
Intersect ENT (NSDQ:XENT) said yesterday that it tapped lead director Kieran Gallahue as its new interim CEO, effective June 5, replacing Lisa Earnhardt who will be stepping away from the corner office to take up a position as head of medical devices for Abbott (NYSE:ABT).
The Menlo Park, Calif.-based company’s board of directors said that it has begun a search process to find a permanent replacement.
“It has been an honor to lead Intersect ENT the past 11 years. I am extremely proud of all that we have accomplished. Together we have worked with physicians to improve the lives of over 300,000 patients, and the team is laser focused on making localized drug delivery the standard of care for chronic sinusitis sufferers. I look forward to watching this exceptional team continue to deliver over the coming years,” Earnhardt said in prepared remarks.
“On behalf of the board and entire team, I want to thank Lisa for her many contributions to our company, and wish her the best. Under her leadership, Intersect ENT has become the leader in evidence-based innovation in the ENT specialty, and I’m excited to take an expanded role during this important time for the company. I look forward to working closely with the talented Intersect ENT team as we continue to drive growth across our portfolio and deliver value for our shareholders,” Gallahue said in a prepared statement.
Newly formed medtech company Theromics said late last month it tapped Ron Murphy as its new CEO, succeeding Thomas Ryan.
The West Bridgewater, Mass.-based company said that Murphy has held CEO roles at other medical device companies across multiple therapeutic platforms, but did not specify any companies by name. Theromics added that it also named Dr. Joseph Amaral to its board of directors.
“I am thrilled to be working with Dr. Dupuy and Dr. Park to commercialize this new technology to optimize thermal ablation and ultimately minimize the recurrence rate of these deadly cancers,” Murphy said in a prepared statement.
“The ability to enlarge and shape ablations and to reduce and eliminate the effects of local blood vessels on tumor recurrence is a leap forward in the minimally invasive management of patients with tumors. It is exciting to join the board of Theromics, the leaders of this new area of patient care,” Amaral said in a press release.
The Alpharetta, Ga.-based company said that it has already begun the search for a permanent CFO, and added that Machan will retain his previous titles and positions while serving as interim CFO.
Prior to joining Avanos, Machan worked for Kimberly-Clark for more than 25 years, serving as strategy senior director for its healthcare business from January 2012 until Avanos, formerly known as Halyard Health, spun off from them in October 2014.
Stericycle (NSDQ:SRCL) said last week that it appointed Janet Zelenka as its chief financial officer and exec VP, effective June 1, replacing former CFO Daniel Ginnetti who is transitioning to become international exec VP.
Prior to joining Lake Forest, Ill.-based Stericycle, Zelenka served as CFO at Essendant, the company said. Prior to her position as CFO, Zelenka served as chief information officer and biz integration senior VP.
“During this transformational time for Stericycle, I am pleased to add a CFO with such a strong breadth of expertise across corporate finance, accounting, information technology and operations. Janet’s proven transformational leadership experience will make her a valuable addition to our team as we implement a global enterprise resource planning platform and reposition Stericycle for long-term growth and improved profitability,” CEO Cindy Miller said in a prepared statement.
Stericycle also announced the addition of Dominic Culotta as chief engineer and exec VP and S. Cory White as communication and related services exec VP.